Quantitative analysis of topoisomerase IIα to rapidly evaluate cell proliferation in brain tumors

Biochemical and Biophysical Research Communications

Volumn 331, Issue 4, 2005, Pages 971-976

  Oda, Masashi ^a   Arakawa, Yoshiki ^a   Kano, Hideyuki ^b   Kawabata, Yasuhiro ^c   Katsuki, Takahisa ^a   Shirahata, Mitsuaki ^a   Ono, Makoto ^a   Yamana, Norikazu ^a   Hashimoto, Nobuo ^a   Takahashi, Jun A ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Kishiwada City Hospital   (Japan)

^c HAMAMATSU ROSAI HOSPITAL   (Japan)

Author keywords

Brain tumor; Quantitative analysis; RT PCR; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A;

ADULT; ANALYTIC METHOD; ARTICLE; BRAIN TUMOR; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD, PRESCHOOL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 21044434746     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.03.224     Document Type: Article

References (29)

1. J.M. Elias Cell proliferation indexes: a biomarker in solid tumors Biotech. Histochem. 72 1997 78 85
2. A. Korshunov, and A. Golanov The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas Arch. Pathol. Lab. Med. 125 2001 892 898
3. S. Wolfsberger, J. Wunderer, I. Zachenhofer, T. Czech, H.G. Bocher-Schwarz, J. Hainfellner, and E. Knosp Expression of cell proliferation markers in pituitary adenomas-correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha Acta Neurochir. (Wien.) 146 2004 831 839
4. T.J. Montine, J.J. Vandersteenhoven, A. Aguzzi, O.B. Boyko, R.K. Dodge, B.J. Kerns, and P.C. Burger Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms Neurosurgery 34 1994 674 679
5. M. Bredel, I.F. Pollack, R.L. Hamilton, P. Birner, J.A. Hainfellner, and J. Zentner DNA topoisomerase IIalpha predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas Int. J. Cancer 99 2002 817 820
6. A. Korshunov, A. Golanov, and V. Timirgaz p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases Acta Neuropathol. (Berl.) 102 2001 271 277
7. H.E. Miettinen, T.A. Jarvinen, U. Kellner, P. Kauraniemi, R. Parwaresch, I. Rantala, H. Kalimo, L. Paljarvi, J. Isola, and H. Haapasalo High topoisomerase IIalpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas Neuropathol. Appl. Neurobiol. 26 2000 504 512
8. K. Taniguchi, T. Wakabayashi, T. Yoshida, M. Mizuno, K. Yoshikawa, A. Kikuchi, N. Nakashima, and J. Yoshida Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas J. Neurosurg. 91 1999 477 482
9. J.C. Wang DNA topoisomerases Annu. Rev. Biochem. 54 1985 665 697
10. J.C. Wang DNA topoisomerases Annu. Rev. Biochem. 65 1996 635 692
11. W.C. Earnshaw, and M.M.S. Heck Topoisomerase II is a structural component of mitotic chromosome scaffolds J. Cell Biol. 100 1985 1706 1715
12. P.C. Goswami, M. Hill, R. Higashikubo, W.D. Wright, and J.L. Roti Roti Radiat. Res. 132 1992 162 167
13. P.C. Goswami, J. Sheren, L.D. Albee, A. Parsian, J.E. Sim, L.A. Ridnour, R. Higashikubo, D. Gius, C.R. Hunt, and D.R. Spitz Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3′-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation J. Biol. Chem. 275 2000 38384 38392
14. P.C. Goswami, J.L. Roti Roti, and C.R. Hunt The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation Mol Cell Biol. 1996 1500 1508
15. N. Adachi, M. Kobayashi, and H. Koyama Cell cycle-dependent regulation of the mouse DNA topoisomerase IIalpha gene promoter Biochem. Biophys. Res. Commun. 230 1997 105 109
16. H. Lage, and M. Dietel Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells J. Cancer Res. Clin. Oncol. 128 1992 349 357
17. Y. Arakawa, H. Bito, T. Furuyashiki, T. Tsuji, S. Takemoto-Kimura, K. Kimura, K. Nozaki, N. Hashimoto, and S. Narumiya Control of axon elongation via an SDF-1alpha/Rho/mDia pathway in cultured cerebellar granule neurons J. Cell Biol. 161 2003 381 391
18. J. Gerdes, H. Lemke, H. Baisch, H.H. Wacker, U. Schwab, and H. Stein Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 J. Immunol. 133 1984 1710 1715
19. K. Roessler, A. Bertalanffy, H. Jezan, A. Ba-Ssalamah, I. Slavc, T. Czech, and H. Budka Proliferative activity as measured by MIB-1 labeling index and long-term outcome of cerebellar juvenile pilocytic astrocytomas J. Neurooncol. 58 2002 141 146
20. J. Orchel, J. Slowinski, U. Mazurek, and T. Wilczok H3 mRNA level as a new proliferative marker in astrocytomas Biochim. Biophys. Acta 1689 2004 42 46
21. P. Sallinen, H. Miettinen, S.L. Sallinen, H. Haapasalo, H. Helin, and J. Kononen Increased expression of telomerase RNA component is associated with increased cell proliferation in human astrocytomas Am. J. Pathol. 150 1997 1159 1164
22. M.V. Seiden, S.W. Ng, J.G. Supko, D.P. Ryan, J.W. Clark, T. Lynch, K.C. Huang, D. Kwiatkowski, A. Skarin, and J.P. Eder Jr. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors Clin. Cancer Res. 8 2002 691 697
23. P.B. Jensen, and M. Sehested DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide Biochem. Pharmacol. 54 1997 755 759
24. H. Takano, K. Kohno, K. Matsuo, T. Matsuda, and M. Kuwano DNA topoisomerase-targeting antitumor agents and drug resistance Anticancer Drugs 3 1992 323 330
25. C.M. Galmarini, X. Thomas, F. Calvo, P. Rousselot, A.E. Jafaari, E. Cros, and C. Dumontet Potential mechanisms of resistance to cytarabine in AML patients Leukoc. Res. 26 2002 621 629
26. S. Kawabata, M. Oka, H. Soda, K. Shiozawa, K. Nakatomi, J. Tsurutani, Y. Nakamura, S. Doi, T. Kitazaki, K. Sugahara, Y. Yamada, S. Kamihira, and S. Kohno Expression and functional analyses of breast cancer resistance protein in lung cancer Clin. Cancer Res. 9 2003 3052 3057
27. D.S. Tews, A. Nissen, C. Kulgen, and A.K. Gaumann Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors J. Neurooncol. 50 2000 227 237
28. A.C. Dingemans, J. van Ark-Otte, S. Span, G.V. Scagliotti, P. van der Valk, P.E. Postmus, and G. Giaccone Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer Lung Cancer 32 2001 117 128
29. R. Zhou, S.M. Frostvik, U. Kronenwett, A. Gruber, J. Liliemark, and E. Liliemark Real-time RT-PCR for the determination of topoisomerase II mRNA level in leukaemic cells Leukoc. Res. 26 2002 487 494